DOJ’s New Whistleblower Program: Fast Cash for Fraud Tips

On October 20, 2026, the Department of Justice unveiled the Fraud Whistleblower Incentive Program (WHIP), formally the National Fraud Enforcement Division Criminal Tip Rewards Pilot Program (the “Program”) — a three-year pilot that pays an up-front reward of $10,000 to $30,000 for tips leading to criminal charges, well before a case resolves through conviction, forfeiture, or appeal. DOJ is relying on its existing statutory authority under 28 U.S.C. § 530C(b)(1)(L) to pay rewards for assistance to the Department, and awards remain entirely discretionary and non-appealable. The Department of the Treasury has committed $25 million to stand up the Program, and tipsters are directed to submit through an intake form at america.gov/fraud (though DOJ reserves discretion to consider tips submitted through other channels as well). For now, the Program is focused on federal health care offenses, with particular emphasis on hospice, home health, day care, and special services fraud.

The headline feature remains the Program’s front-loaded structure: DOJ wants to give tipsters “certainty about the amount and timing” of a reward, rather than making them wait until prosecution. A reward is paid at or around the time charges are filed (meaning an unsealed indictment, information, or complaint), and a tipster can still pursue a larger payout later under other programs, including the Criminal Division’s Corporate Whistleblower Awards Pilot Program.

Who is Eligible for the Payout?

The eligibility criteria matter as much as the headline number. Only individuals — not companies — can submit, and the information must be original, voluntary, truthful, and complete, submitted before DOJ, another law enforcement agency, or a civil regulator makes any related inquiry. Tipsters who meaningfully participated in the reported scheme are excluded, as are current DOJ personnel, their close relatives, and foreign government officials. Notably, the Program also walls off information obtained through attorney-client privileged communications, through compliance, audit, or internal investigation functions, or in connection with legal representation of a client for personal benefit — though limited exceptions apply where disclosure is necessary to prevent ongoing harm or where at least 120 days have elapsed since the information was provided to company leadership. Submissions are confidential, and anonymous tips are permitted only through counsel.

Several additional eligibility and discretion points deserve attention. A tipster who participated in the scheme can still qualify if their role was “plainly among the least culpable of those involved,” but any direct financial benefit outside ordinary compensation is disqualifying. The Department also expressly reserves discretion to deny a reward where the tipster held a senior or decision-making role over the misconduct, contributed to compliance-system failures, built a culture that deprioritized compliance, or received red flags and failed to act.  These factors will matter most to mid-level and senior managers weighing whether to come forward. On the company side, DOJ has signaled it will treat enforcement (or attempted enforcement) of confidentiality or non-disclosure agreements against would-be tipsters as a negative factor in assessing cooperation credit and compliance-program effectiveness, and retaliation against a whistleblower can both erode cooperation credit and prompt stand-alone enforcement action. Each distinct tip is eligible for only one award, and the Department has reserved authority to permanently bar any person who submits frivolous or fraudulent tips.

Why is DOJ Offering This?

The Program traces directly to Assistant Attorney General Colin McDonald’s October 1 Directive 26-12, which ordered the Fraud Division to design programs that “appropriately incentivize whistleblowers to bring forward credible information pertaining to fraud.” That’s the same directive we flagged in our prior post, which prioritizes health care fraud schemes involving controlled substance distribution and Federal Food, Drug, and Cosmetic Act violations. With WHIP now live — and its compliance-function carve-outs raising real stakes for how internal reports are handled — life sciences and health care companies sit squarely at the intersection of DOJ’s narrowed enforcement focus and its newest, fastest-paying incentive for insiders to talk.

What Should Companies Do?

How all this will work out remains to be seen.  One open question is whether reporting criminal violations of the Federal Food, Drug and Cosmetic Act and the Controlled Substances Act will be eligible as “federal health care offenses” (they were included as such in Direct 26-12).  Another is whether this policy will change the filing or litigation practices of relators filing qui tam complaints as whistleblowers under the False Claims Act.  Specifically, how will the Program’s requirement that information “materially add[ ] to the information the Department already possesses” interact with the False Claims Act’s first-to-file bar and public disclosure bar, and how will a WHIP submission impact a later qui tam filing by the same whistleblower.

Finally, the Program certainly will place a new set of pressures on entities receiving internal audits or investigative reports to take prompt action to prevent ongoing harm within 120 days of the report. Life sciences general counsel and compliance officers should expect WHIP to put greater pressure on companies to act quickly upon receipt of an internal report of federal health care fraud violations, and to calibrate internal hotline, investigation, and remediation workflows to this new reality.